Saudi Policy Framework Drives Gulf Biotech Investment Ahead of 2026 Summit

RIYADH’S BIOTECH CAPITAL MODEL: HOW SOVEREIGN WEALTH AND GOVERNMENT PROCUREMENT RESHAPE DEAL STRUCTURES

Saudi Arabia’s National Biotechnology Strategy, with targets running to 2030 and 2040, is the policy document against which most Gulf biotech capital is now deployed. That strategy, and the sovereign, regulatory, and institutional machinery built around it, will take center stage at the Riyadh Global Medical Biotechnology Summit (RGMBS) 2026, scheduled for 14 to 16 September in the Saudi capital.

The distinction from Western models matters because it reshapes risk, underwriting, and the basic proposition a multinational partner evaluates. In the Gulf, sovereign wealth funds and government strategy drive capital deployment, not institutional venture investors chasing asset novelty. The region holds the world’s largest concentration of sovereign-owned assets relative to GDP, at more than 1.4 times as of 2024, according to EY analysis of Middle East and North Africa sovereign wealth funds. That compares to roughly 0.1 times in Europe and Asia. Capital operating on that scale, and on government timelines, behaves differently from venture capital.

For global pharmaceutical companies, the Gulf occupies a strategic position between Europe, Asia, and Africa, with logistics infrastructure suited to serve as a distribution and manufacturing base well beyond its own borders. Novo Nordisk’s decision in May 2026 to build a regional distribution center in the UAE illustrates the logic. The facility is one of three such hubs the company operates worldwide, intended to serve up to 70 countries across the Gulf, Africa, and Central Asia while supporting treatment access for more than 2.6 million patients. Saudi Arabia follows the same pattern. Pfizer operates a manufacturing facility at King Abdullah Economic City, and the Ministry of Health has signed agreements with Sanofi to localize insulin production, explicitly framed around export potential to wider Middle East markets.

H.E. Prof. Bandar Al-Knawy, Chief Executive Officer of the Ministry of National Guard Health Affairs and President of King Saud bin Abdulaziz University for Health Sciences, has emphasized the role of research, localization, industrial capability, and public-private partnerships in advancing these national priorities. For investors, that connection is critical: many emerging deal structures in the Kingdom translate national biotechnology priorities directly into commercial capacity.

The data on GCC healthcare investment, compiled by JLL across 2021 to April 2025, recorded close to 400 transactions in the region. Saudi Arabia and the UAE accounted for approximately 92 percent of that activity, with the UAE recording 198 deals and Saudi Arabia 170. The composition included 170 early-stage funding rounds, 91 mergers and acquisitions, and 27 initial public offerings. Within that broader healthcare sector, biotechnology accounts for 15 transactions and pharmaceuticals for 25, while clinics and outpatient services account for 99 and hospitals for 42. Therapeutics and platform biotechnology sit earlier on the investment curve than the wider healthcare sector, with the region’s capital infrastructure already established at scale in adjacent segments.

Sovereign and state-backed vehicles are the largest source of capital deployment. Lifera, the contract development and manufacturing organization established in 2023 and wholly owned by the Public Investment Fund, represents the clearest example of sovereign capital deployed to build industrial capability directly rather than to take financial positions. That distinction changes the counterparty dynamics fundamentally. A sovereign-owned manufacturer building against a national localization target behaves differently from a commercial CDMO optimizing for utilization.

Government research funding flows through the Research, Development and Innovation Authority and related programs, including the Saudi Innovation Grants Program launched in December 2024, which provides non-dilutive funding to small and medium enterprises. Domestic venture capital is building alongside it. Beta Lab reported more than 200 funding applications in a single year, the majority from international startups. International capital is also entering through structured vehicles. At a previous RGMBS, SBI Holdings signed with the Ministry of Investment, KAIMRC, and BIM Ventures to launch a fund directing 50 million dollars into Japanese biotechnology startups at KAIMRC.

Guaranteed offtake agreements represent the single most consequential mechanism making these deals work. When government commits to purchase a defined output volume, a manufacturing investment converts from a demand-risk bet into a capacity-delivery problem. For biologics and vaccines, where facility costs are high, that fundamentally changes how the investment is underwritten and priced.

The incentive stack extends beyond offtake. Tax credits of up to 50 percent on Saudi worker payroll and training for ten years, salary support through the Human Resources Development Fund, and special economic zones offering tax reductions and eased foreign talent rules all support the structure. Technology transfer recurs throughout: an international partner brings capability, a local entity builds and operates, and government procurement underwrites demand.

Regulatory predictability underpins the entire framework. The Saudi Food and Drug Authority has been benchmarked by the World Health Organization at Maturity Level 4, the highest classification, and has published dedicated frameworks for advanced therapy medicinal products, including a classification guideline through which developers can request formal advice before clinical data exists. For an investor, regulatory pathway clarity is a direct input into risk pricing.

Institutional infrastructure is being built in parallel. The Riyadh Biocentral Foundation, approved as a non-profit entity under the Royal Commission for Riyadh City with a board chaired by the Crown Prince, carries a mandate covering biotechnology zones and facilities, incubation of early-stage projects, and partnerships with international biotech centers. For a company weighing a physical footprint in the Kingdom, this is the body responsible for the site and cluster infrastructure it would occupy.

Across its first three editions, RGMBS has generated 59 agreements. The 2024 edition alone produced 40, with associated deal value above 100 million dollars. The composition reveals the prevailing model more clearly than the count. Those 2024 agreements spanned counterparties across the United States, Germany, Japan, China, and Saudi Arabia, covering cell and gene therapy, AI-based diagnostics, RNA technologies, vaccines and biosimilars, stem cells, precision medicine, and research infrastructure. Most were structured as memoranda of understanding between KAIMRC and an international partner. The national research institution acts as anchor counterparty, and international organizations partner into its infrastructure and patient access rather than building independently.

By contrast, recent activity on the commercial side signals a maturing domestic market. SPIMACO, the Kingdom’s largest vertically integrated pharmaceutical manufacturer, has established a wholly owned subsidiary, SPIMACO Bio, to develop and manufacture biological, gene, and cell therapy products, framed explicitly around localization and technology transfer. On the public markets, Sudair Pharmaceutical Company has filed with the Capital Market Authority to offer shares on the main market, following Jamjoom Pharma in 2023 and Avalon Pharma in 2024. Saudi pharmaceutical assets now have a visible domestic exit route, not only a partnering one.

RGMBS 2026 runs 14 to 16 September in Riyadh. The investment theme runs across Day 2, covering AI-enabled biotechnology platforms, vaccine funding models, and a session on de-risking investment in biomanufacturing that addresses offtake, public-private partnership, and blended finance structures. The program opens with a session on the National Biotechnology Strategy, followed by a panel on global partnerships in biotech. Alongside the stage program, the summit runs structured business matchmaking and a dedicated agreement signing area. The people who set the localization targets, the people who underwrite the offtake, and the people who sign the agreements are in the same building for three days. Full scientific program and delegate registration are available at rgmbs.org.